Will New Antibiotic Incentives GAIN Investors’ Backing?
Executive Summary
The GAIN Act is intended to spur development of new antibiotics, but incentives like extended market exclusivity and priority review, while important benefits, may not be enough to get investors off the sidelines.
You may also be interested in...
Cellceutix Buys Mid-Stage Antibiotic Brilacidin On The Cheap
With brilacidin developer PolyMedix having filed for bankruptcy, Cellceutix will acquire the company’s assets for $2.1 million in cash and 1.4 million shares of stock.
Seeking Funds For Phase III Antibiotic, Paratek Files For IPO
The Boston-based drug developer believes it has resolved the regulatory issues that led to the dissolution of a partnership with Novartis around the drug omadacycline.
Antibiotic Legislation Offers Big GAIN For Small Firm: Rib-X Extends Delafloxacin Exclusivity
Rib-X is among the first to take advantage of the Generating Antibiotic Incentives Now provisions of the FDA reauthorization legislation with five years’ extra exclusivity for its lead broad spectrum antibiotic candidate, a next-generation fluoroquinolone. Designation for the program came swiftly, company says.